Regulatory update: GSK and XenoPort submit supplemental new drug application to FDA
Posted: 9 August 2011 | | No comments yet
GSK and XenoPort, Inc. request approval of Horizant™…


GlaxoSmithKline (NYSE and LSE: GSK) and XenoPort, Inc. (Nasdaq: XNPT) announced today that a supplemental New Drug Application (sNDA) has been submitted to the U.S. Food and Drug Administration (FDA) requesting approval of Horizant™ (gabapentin enacarbil) Extended-Release Tablets for the management of postherpetic neuralgia (PHN) in adults.
The sNDA has been submitted to the FDA by GSK.